Usefulness of CA 19-9 for pancreatic cancer screening in patients with new-onset diabetes
- Authors
- Choe, Jung Wan; Kim, Hyo Jung; Kim, Jae Seon; Cha, Jaehyung; Joo, Moon Kyung; Lee, Beom Jae; Park, Jong-Jae; Bak, Young-Tae
- Issue Date
- 6월-2018
- Publisher
- ELSEVIER SCIENCE BV
- Keywords
- Diabetes mellitus; Pancreatic neoplasms; Early detection of cancer; Carbohydrate antigen 19-9; Bilirubin
- Citation
- HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, v.17, no.3, pp.263 - 268
- Indexed
- SCIE
SCOPUS
- Journal Title
- HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
- Volume
- 17
- Number
- 3
- Start Page
- 263
- End Page
- 268
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/75077
- DOI
- 10.1016/j.hbpd.2018.04.001
- ISSN
- 1499-3872
- Abstract
- Background: Generally, carbohydrate antigen 19-9 (CA 19-9) is not useful for screening pancreatic cancer in the asymptomatic general population. This study aimed to evaluate the utility of CA 19-9 level as a screening indicator of pancreatic cancer in asymptomatic patients with new-onset diabetes. Methods: We retrospectively reviewed the medical records of patients who visited our health promotion center for health check-ups without cancer related symptoms from January 2005 to January 2014, and were newly diagnosed with diabetes mellitus (DM) within 2 years before their visit. Results: Of the 5111 asymptomatic patients with new-onset DM (<2 years) selected for analyses, 87 (1.7%) eventually developed pancreatic cancer after the health check-up. In the subgroup of 322 patients with high total bilirubin levels (>1.7 mg/dL) at the screening time, 42 (73.7%) of 57 patients with high CA 19-9 levels (>37 IU/mL) had been diagnosed as pancreatic cancer during follow-up period and 12 (4.5%) of 265 patients with normal CA 19-9 levels had finally developed pancreatic cancer (OR =16.3). In the subgroup of 4789 patients with normal bilirubin levels, pancreatic cancer had been detected in 20 (3.8%) of 522 patients with high CA 19-9 level, while only 13 (0.3%) in 4267 patients with normal CA 19-9 levels (OR= 12.6), respectively. Conclusion: CA 19-9 levels after a diagnosis of new-onset DM could be a useful biomarker of pancreatic cancer, especially in patients with high serum bilirubin. (C) 2018 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.